Actively Recruiting
The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.
Led by University of Toronto · Updated on 2025-11-26
1100
Participants Needed
1
Research Sites
511 weeks
Total Duration
On this page
Sponsors
U
University of Toronto
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Despite the availability of medications, many people around the world continue to live with long-term health problems like heart disease, stroke and diabetes. In Canada, heart disease is a leading cause of death. Managing these health issues can be done by changing diet and lifestyle. Specific ways of eating have been proven to improve risk for heart disease and stroke. However, because doctors often have limited time, nutrition education, and lack of tools for counseling patients on nutrition, they can often only provide minimal support to help patients make necessary lifestyle changes. Digital tools and mobile applications offer an opportunity to involve doctors and patients in delivering nutrition interventions. This approach has the potential to save time, provide education, and reduce healthcare costs. This study is being done to understand the effect of a digital heart health program added to standard of care, compared with standard of care alone on heart health. All eligible participants in this study will be randomized (determined by chance) to one of two possible interventions: 1) a digital heart health program + standard of care; 2) standard of care. Standard is care is defined as the best practice based on guidelines for the treatment of a condition. All participants will be followed for seven years and will be asked to complete online questionnaires and complete blood work at their nearest LifeLabs clinic, as well as wear a continuous glucose monitor and wrist actigraph (at 3 time points in the first year). In addition, participants randomized to the digital heart health program + standard of care will be expected to use the heart health app and join 16 online synchronous sessions over the first year. After seven years, the intervention phase of the study will end and the study will become a cohort study. All participants at the 7-year time point will be invited to use the heart health app. As part of the cohort study, participants will be asked to continue completing the same questionnaires online and completing bloodwork at their nearest LifeLabs every four years for the duration of their participation in the cohort study. The main questions this study aims to answer are: 1. Will a digital heart health program added to standard of care result in a clinically meaningful reduction in blood cholesterol and other risk factors after 1-year compared to standard of care alone? 2. Will a digital heart health program added to standard of care result in a reduction in major cardiovascular events after 7-years compared to standard of care alone? 3. Are the observed effects sustained beyond the 7-years of the intervention? We hypothesize that the digital heart health program added to standard of care will result in a clinically meaningful reduction in blood cholesterol and other risk factors for heart disease after 1-year and reduce major cardiovascular events after 7-years compared to standard of care alone.
CONDITIONS
Official Title
The Effect of a Digital Heart Health App and Lifestyle Intervention for Heart Disease in Primary Care.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be taking statin medication with or without other antihyperlipidemic therapy at a stable dose for at least 3 months
- Be male or female aged 45 years or older with established atherosclerotic cardiovascular disease (such as prior heart attack, stroke, coronary procedures, carotid disease, stable angina, peripheral artery disease, or abdominal aortic aneurysm)
- Or be male or female aged 50 years or older with type 2 diabetes requiring medication plus at least one additional risk factor (such as older age, smoking, hypertension treated for at least 6 months, chronic kidney disease, or diabetic retinopathy)
- Be on stable doses for at least 3 months of all cholesterol, blood sugar, blood pressure, and weight management therapies
- Have a family physician in Ontario and a valid Ontario Health Card
- Have regular access to an online portal
- Be proficient in English
You will not qualify if you...
- Have a major disease expected to cause death within 2 years, except cardiovascular disease
- Have active severe liver disease or malabsorption disorders
- Have drug or alcohol abuse disorders within the past 6 months
- Have allergies or intolerance to soy protein, tree nuts, peanuts, or seeds
- Have planned coronary intervention or major surgery
- Have participated in another clinical trial within the past 3 months
- Have end stage renal disease requiring dialysis or very low kidney function (eGFR <30 mL/min)
- Have any condition or treatment posing a risk or not in the patient’s best interest as judged by the investigator
- Have severe heart failure (New York Heart Association class IV)
- Have mental or psychological impairments affecting study adherence
- Have known AIDS (HIV-positive without AIDS allowed)
- If female, planning pregnancy within the first year of the study
- Unable to provide informed consent or insufficient English comprehension
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
C. David Naylor Building
Toronto, Ontario, Canada, M5S1A8
Actively Recruiting
Research Team
L
Laura Chiavaroli, PhD
CONTACT
J
John L Sievenpiper, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here